(Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, a spokesperson told Reuters, despite ...

Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...

CVS Health Inc. (NYSE:CVS) said it will not add Gilead Sciences Inc.’s (NASDAQ:GILD) new HIV prevention drug Yeztugo to its commercial plans. In June, the U.S. Food and Drug Administration (FDA) ...

Needham upgraded Gilead Sciences (NASDAQ:GILD) to Buy from Hold on Friday, citing a physical survey to suggest that the company’s new twice-yearly injectable for HIV prevention, Yeztugo, is on track ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug that offers 100% protection with its twice-yearly injections. It's a landmark ...

Oral preexposure prophylaxis (PrEP) has played a significant role in Australia’s reduction of new HIV infections, but experts have sounded the alarm over ongoing challenges. They suggested that new, ...

A new pre-exposure prophylaxis (PrEP) drug has shown promise as a once-monthly oral pill to help prevent HIV. PrEP plays a key part in reducing the number of new HIV infections by stopping the virus ...

Protecting public health abroad benefits Americans. In a globalized world, diseases and their social and economic impacts do not stay within national boundaries. Increased rates of untreated HIV in ...

Shares of Gilead Sciences, Inc. (GILD) tumbled 2.2% on Aug. 21, after pharmacy benefit manager CVS Health (CVS) decided not to add the former’s new HIV prevention drug, Yeztugo (lenacapavir), to its ...